citiusonc.com - נכסים נקיים למניה בודדת CTOR

This daily price chart for Citius Oncology, Inc. (CTOR) reflects the price action of an asset currently valued at 0.38. The business does not generate sales, as it directs resources toward drug trials, resulting in losses. Citius Oncology, Inc. (CTOR) develops targeted molecules for precision tumor destruction. Growth prospects rely on alliances with biotech behemoths to bring new lymphoma therapies to market.

This indicator is calculated as the difference between the company's total assets and all liabilities, divided by the number of shares outstanding, which determines the actual value of an investor's stake upon business liquidation. The book value per share trend for Citius Oncology, Inc. (CTOR) allows for an assessment of the issuer's financial stability during the period leading up to the final regulatory approval of its T-cell lymphoma drug.